Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
NCT05986773 · Stadtspital Zürich · PHASE4 · terminated · last registry update 2025-02-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment in both centers” | – | Registry record, Stadtspital Zürich |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC12A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-29Also stopped (withdrawn): Prisma Health-Upstate, Bumetanide, intranasal 4mg (NCT07375212)
- 2026-01-14Results posted on the registry: Mayo Clinic, Bumetanide + Furosemide (NCT06036914)
- 2026-01-13Results posted on the registry: Boehringer Ingelheim, Rosuvastatin + Digoxin (NCT05741372)
- 2026-01-09Results posted on the registry: Boehringer Ingelheim, Zongertinib + Dabigatran-etexilate (NCT06504862)
- 2025-12-08Results posted on the registry: University of Delaware, a drug against SLC12A1 (NCT05480722)
- 2025-10-31Phase 3 first posted: Sarfez Pharmaceuticals, Inc., Combination Product: FDC of spironolactone and ER torsemide + Combination Product: Stabilized doses of loop diuretic and finerenone (NCT07223502)
- 2025-10-27Results posted on the registry: Emory University, Furosemide (NCT05779943)
- 2025-10-16Results posted on the registry: Duke University, Torsemide + Furosemide (NCT03296813)
- 2025-09-16Also stopped (terminated): Rush University Medical Center, Furosemide Injection + Albumin Human (NCT04216784)
- 2025-08-08Results posted on the registry: Vrije Universiteit Brussel, Intravenous acetazolamide 500 mg OD + Intravenous bumetanide TID (NCT05411991)
- 2025-08-08Results posted on the registry: Washington State University, MetFORMIN Oral Solution + Cimetidine 400 MG (NCT05365451)
- 2025-07-16Results posted on the registry: University of Texas Southwestern Medical Center, Furoscix + Diuretic Therapy (NCT05528588)
- 2025-07-02Phase 3 first posted: Sarfez Pharmaceuticals, Inc., Torsemide and Spironolactone tablet + Torsemide Tablets and Spironolactone Tablets (NCT07046975)
- 2025-06-29Phase 3 first posted: Sarfez Pharmaceuticals, Inc., FDC (24 mg ER torsemide and 30 mg Spironolactone) without food + FDC (24 mg ER torsemide and 30 mg Spironolactone) with food (NCT07043634)
- 2025-06-12Phase 3 first posted: University of Texas Southwestern Medical Center, Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor (NCT07018297)
- 2025-06-11Phase 3 first posted: Sarfez Pharmaceuticals, Inc., 10 mg Torsemide tablet + 25 mg Aldactone (Spironolactone) tablet (NCT07015671)
- 2025-06-06Phase 3 first posted: Instituto de Investigación Sanitaria Aragón, Furosemide 20 Milligrams (NCT07008365)
- 2025-06-05Results posted on the registry: National Cancer Institute (NCI), Rituximab + Conditioning chemotherapy (NCT02356159)
- 2025-05-14Also stopped (suspended): Sclnow Biotechnology Co., Ltd., Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) + conventional treatment (NCT03180450)
- 2025-05-09Results posted on the registry: Rush University Medical Center, Furosemide Injection + Albumin Human (NCT04216784)
- 2025-04-23Phase 3 first posted: Stacy Johnson, Bumetanide + Furosemide (NCT06941415)
- 2025-02-20Also stopped (terminated): Damascus University, mono nuclear cells injection + Digoxin+furosemide+captopril (NCT04893629)
- 2025-02-20Also stopped (withdrawn): Jan Kochanowski University, Furosemide Pill 150% equivalent iv dose + Furosemide Pill 200% equivalent iv dose (NCT05652322)
- 2025-01-14Results posted on the registry: University Hospital Tuebingen, Amiloride + Furosemide (NCT05079789)
- 2025-01-14Also stopped (terminated): University Hospital Tuebingen, Amiloride + Furosemide (NCT05079789)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision